New strategies in esophageal carcinoma: promises and problems

Affiliations

¹ Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.
² Department of Thoracic Surgery, Ningxia Medical University General Hospital, Yinchuan 750004, China.
³ Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA;; Center for Esophageal Disease and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27519, USA.

Comment

Zhaohui Xiong et al. J Thorac Dis. 2016 Nov.

. 2016 Nov;8(11):E1501-E1504.

doi: 10.21037/jtd.2016.11.22.

¹ Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.
² Department of Thoracic Surgery, Ningxia Medical University General Hospital, Yinchuan 750004, China.
³ Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA;; Center for Esophageal Disease and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27519, USA.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints.
Wang VE, Grandis JR, Ko AH. Wang VE, et al. Clin Cancer Res. 2016 Sep 1;22(17):4283-90. doi: 10.1158/1078-0432.CCR-16-0292. Epub 2016 Jul 1. Clin Cancer Res. 2016. PMID: 27370606 Review.

1. Wang VE, Grandis JR, Ko AH, et al. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res 2016;22:4283-90. 10.1158/1078-0432.CCR-16-0292 - DOI - PubMed
1. Jackie Oh S, Han S, Lee W, et al. Emerging immunotherapy for the treatment of esophageal cancer. Expert Opin Investig Drugs 2016;25:667-77. 10.1517/13543784.2016.1163336 - DOI - PubMed
1. Schrump DS, Nguyen DM. Novel molecular targeted therapy for esophageal cancer. J Surg Oncol 2005;92:257-61. 10.1002/jso.20367 - DOI - PubMed
1. Woo J, Cohen SA, Grim JE. Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf) 2015;3:316-29. - PMC - PubMed
1. Zhang L, Ma J, Han Y, et al. Targeted therapy in esophageal cancer. Expert Rev Gastroenterol Hepatol 2016;10:595-604. 10.1586/17474124.2016.1140036 - DOI - PubMed